دورية أكاديمية
أعرض في EDS

C1GalT1 expression reciprocally controls tumour cell-cell and tumour-macrophage interactions mediated by galectin-3 and MGL with double impact on cancer development and progression.

التفاصيل البيبلوغرافية
العنوان: C1GalT1 expression reciprocally controls tumour cell-cell and tumour-macrophage interactions mediated by galectin-3 and MGL with double impact on cancer development and progression.
المؤلفون: Wan Y; Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Adair K; Centre for Proteome Research, University of Liverpool, Liverpool, UK., Herrmann A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Shan X; Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Xia L; Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Duckworth CA; Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Yu LG; Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. lgyu@liv.ac.uk.
المصدر: Cell death & disease [Cell Death Dis] 2023 Aug 23; Vol. 14 (8), pp. 547. Date of Electronic Publication: 2023 Aug 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group
مواضيع طبية MeSH: Galectin 3*/genetics , Colonic Neoplasms*/genetics, Chick Embryo ; Humans ; Animals ; Mice ; Galactose ; Glycosylation ; Macrophages ; Tumor Microenvironment
مستخلص: Although most cell membrane proteins are modified by glycosylation, our understanding of the role and actions of protein glycosylation is still very limited. β1,3galactosyltransferase (C1GalT1) is a key glycosyltransferase that controls the biosynthesis of the Core 1 structure of O-linked mucin type glycans and is overexpressed by many common types of epithelial cancers. This study reports that suppression of C1GalT1 expression in human colon cancer cells caused substantial changes of protein glycosylation of cell membrane proteins, many of which were ligands of the galactoside-binding galectin-3 and the macrophage galactose-type lectin (MGL). This led to significant reduction of cancer cell proliferation, adhesion, migration and the ability of tumour cells to form colonies. Crucially, C1GalT1 suppression significantly reduced galectin-3-mediated tumour cell-cell interaction and galectin-3-promoted tumour cell activities. In the meantime, C1GalT1 suppression substantially increased MGL-mediated macrophage-tumour cell interaction and macrophage-tumour cell phagocytosis and cytokine secretion. C1GalT1-expressing cancer cells implanted in chick embryos resulted in the formation of significantly bigger tumours than C1GalT1-suppressed cells and the presence of galectin-3 increased tumour growth of C1GalT1-expressing but not C1GalT1-suppressed cells. More MGL-expressing macrophages and dendritic cells were seen to be attracted to the tumour microenvironment in ME C1galt1 -/- /Erb mice than in C1galt1 f/f /Erb mice. These results indicate that expression of C1GalT1 by tumour cells reciprocally controls tumour cell-cell and tumour-macrophage interactions mediated by galectin-3 and MGL with double impact on cancer development and progression. C1GalT1 overexpression in epithelial cancers therefore may represent a fundamental mechanism in cancer promotion and in reduction of immune response/surveillance in cancer progression.
(© 2023. The Author(s).)
References: Histol Histopathol. 2016 Jun;31(6):613-21. (PMID: 26758176)
Cell Death Dis. 2014 Oct 02;5:e1438. (PMID: 25275599)
J Neuroinflammation. 2019 Jun 27;16(1):130. (PMID: 31248427)
Innate Immun. 2013 Feb;19(1):98-111. (PMID: 22732734)
J Biol Chem. 2013 Mar 8;288(10):6921-9. (PMID: 23329828)
Mol Cancer. 2010 Jun 18;9:154. (PMID: 20565834)
J Biol Chem. 2015 Aug 14;290(33):20159-66. (PMID: 26124270)
J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64. (PMID: 11547903)
Oncotarget. 2016 Dec 13;7(50):83570-83587. (PMID: 27835877)
Biochem J. 2020 Apr 30;477(8):1541-1564. (PMID: 32348475)
Sci Rep. 2017 Jul 25;7(1):6362. (PMID: 28743911)
Oncogene. 2011 Aug 4;30(31):3468-76. (PMID: 21399662)
Cancer Cell. 2019 Mar 18;35(3):347-367. (PMID: 30889378)
PLoS One. 2013;8(3):e59792. (PMID: 23536887)
Immunobiology. 2015 Feb;220(2):185-92. (PMID: 25454488)
Clin Cancer Res. 2013 Apr 1;19(7):1693-704. (PMID: 23401226)
Exp Physiol. 2006 Jan;91(1):153-61. (PMID: 16239253)
J Biol Chem. 2007 Jan 5;282(1):773-81. (PMID: 17090543)
Front Oncol. 2014 Jun 16;4:138. (PMID: 24982845)
J Exp Med. 2015 Apr 6;212(4):435-45. (PMID: 25753580)
Nat Rev Cancer. 2017 Aug;17(8):457-474. (PMID: 28706266)
Oncotarget. 2014 Apr 30;5(8):2096-106. (PMID: 24758762)
BMC Cancer. 2015 Aug 08;15:577. (PMID: 26253167)
Gastroenterology. 2016 Jul;151(1):152-164.e11. (PMID: 27059389)
Cell Death Differ. 2017 Nov;24(11):1937-1947. (PMID: 28731466)
J Immunol. 2008 Sep 1;181(5):3148-55. (PMID: 18713985)
Science. 2013 Jan 18;339(6117):286-91. (PMID: 23329041)
Nat Rev Drug Discov. 2018 Dec;17(12):887-904. (PMID: 30361552)
Breast Cancer Res Treat. 2010 Jan;119(2):283-93. (PMID: 19238537)
Annu Rev Pathol. 2015;10:473-510. (PMID: 25621663)
Nat Rev Cancer. 2019 Jan;19(1):9-31. (PMID: 30532012)
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):E4066-75. (PMID: 25118277)
Bio Protoc. 2019 Dec 20;9(24):. (PMID: 31867411)
J Exp Med. 2010 Aug 30;207(9):1981-93. (PMID: 20713592)
Oncogene. 2018 Oct;37(43):5780-5793. (PMID: 29930379)
Leuk Lymphoma. 2021 Jan;62(1):45-57. (PMID: 32856983)
Curr Opin Struct Biol. 2019 Jun;56:87-96. (PMID: 30703750)
Am J Pathol. 2019 Apr;189(4):900-910. (PMID: 30653955)
Mol Cancer. 2015 May 29;14:109. (PMID: 26021314)
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201)
Eur J Immunol. 2012 Apr;42(4):936-45. (PMID: 22531918)
Cancer Res. 2009 Sep 1;69(17):6799-806. (PMID: 19690136)
J Biol Chem. 2017 May 19;292(20):8381-8389. (PMID: 28364041)
Oncotarget. 2016 Nov 1;7(44):71673-71685. (PMID: 27765933)
Annu Rev Biochem. 2004;73:491-537. (PMID: 15189151)
Cell Mol Life Sci. 2020 Feb;77(4):593-605. (PMID: 31485715)
Cytokine Growth Factor Rev. 2010 Oct;21(5):331-44. (PMID: 21115385)
Oncotarget. 2015 Mar 20;6(8):6123-35. (PMID: 25762620)
Mol Cancer Res. 2023 Jul 5;21(7):664-674. (PMID: 37040171)
Oncogenesis. 2015 Feb 09;4:e138. (PMID: 25664931)
HLA. 2016 Dec;88(6):275-286. (PMID: 27679419)
Glycobiology. 2014 Oct;24(10):886-91. (PMID: 25138305)
Nat Immunol. 2006 Nov;7(11):1200-8. (PMID: 16998493)
J Leukoc Biol. 2013 Aug;94(2):315-23. (PMID: 23744646)
J Proteome Res. 2019 Mar 1;18(3):1125-1132. (PMID: 30582698)
Front Cell Dev Biol. 2021 Jul 07;9:707970. (PMID: 34307388)
Cell Metab. 2019 Jul 2;30(1):36-50. (PMID: 31269428)
J Cell Mol Med. 2020 Jan;24(1):362-370. (PMID: 31633299)
Cancers (Basel). 2021 Dec 15;13(24):. (PMID: 34944925)
J Biol Chem. 2012 Dec 28;287(53):44684-93. (PMID: 23118221)
Genes Immun. 2014 Dec;15(8):511-20. (PMID: 25056447)
Cell Death Discov. 2017 Jul 17;3:17044. (PMID: 28725490)
Cancer Lett. 2011 Dec 27;313(2):123-8. (PMID: 21974805)
Semin Immunol. 2014 Feb;26(1):38-47. (PMID: 24602448)
Nat Rev Cancer. 2018 Jul;18(7):452-464. (PMID: 29643473)
Nat Rev Immunol. 2018 Jun;18(6):374-389. (PMID: 29581532)
Nat Rev Cancer. 2005 Jan;5(1):29-41. (PMID: 15630413)
J Exp Clin Cancer Res. 2018 Aug 29;37(1):207. (PMID: 30157903)
Nat Rev Immunol. 2018 Oct;18(10):635-647. (PMID: 30057419)
Cancer Lett. 2015 Oct 28;367(2):103-7. (PMID: 26188281)
Glycoconj J. 2007 Nov;24(8):411-20. (PMID: 17457671)
Ann Med. 2012 Sep;44(6):542-54. (PMID: 21585247)
المشرفين على المادة: 0 (Galectin 3)
X2RN3Q8DNE (Galactose)
تواريخ الأحداث: Date Created: 20230823 Date Completed: 20230825 Latest Revision: 20230826
رمز التحديث: 20230826
مُعرف محوري في PubMed: PMC10447578
DOI: 10.1038/s41419-023-06082-7
PMID: 37612278
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-4889
DOI:10.1038/s41419-023-06082-7